SUNP Stock Research, Signals & Filings
Drillr aggregates AI research, SEC filings, earnings signals, alt-data and financial tables for SUNP. 3 published articles.
Latest Research
OGN: Sun Pharma Locks $12B Buyout, Below Rumored Range
Sun Pharma confirmed a $12 billion Organon acquisition on April 27, $1B below the rumored price but still likely to pressure SUNP shares 4-7% on dilution concerns while OGN rallies 9-15% on the acquisition premium over the next 1-3 trading days.
OGNOGN: Sun Pharma Locks $12B Deal, 90% Below Bid Range
Sun Pharma and Organon announced a definitive $12 billion acquisition agreement on April 27, settling what Wall Street had priced as a 90% no-deal scenario. Organon faces 22-28% upside on the confirmed premium while Sun Pharma confronts 5-7% downside on overpayment concerns, with the thesis breaking if either stock moves >10% on unrelated news before deal close.
OGNOGN: Sun Pharma's $12B Buyout Lands $1B Below Rumored Price
Sun Pharma confirmed a $12 billion Organon acquisition on April 27, $1 billion below the rumored price. The market is treating this as neutral-to-negative for SUNP, but the deal delivers immediate scale in women's health and biosimilars at 1.2x revenue, with $450M+ in synergies driving 20%+ upside over 12-18 months as earnings accretion becomes visible.
OGN
Track SUNP with Drillr
SEC filings, earnings calls, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try drillr.ai for free